Melpomeni Fani
Basel, BS 4031, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 71 publications
Erratum for: 61Cu-NODAGA Prostate-specific Membrane Antigen Imaging and Therapy for Prostate Cancer: Phase 1 Trial of a New Class of 61Cu-labeled PET Radiotracers.
Journal: Radiology
Published: July 28, 2026
Radiolabelled somatostatin receptor antagonist versus agonist for peptide receptor radionuclide therapy in patients with metastatic pheochromocytoma or paraganglioma: a retrospective pilot study.
Journal: European journal of nuclear medicine and molecular imaging
Published: May 30, 2026
61Cu-NODAGA Prostate-specific Membrane Antigen Imaging and Therapy for Prostate Cancer: Phase 1 Trial of a New Class of 61Cu-labeled PET Radiotracers.
Journal: Radiology
Published: December 09, 2025
Novel nastorazepide-based radioligands demonstrate effective cholecystokinin-2 receptor targeting with potential for theranostic applications.
Journal: Theranostics
Published: December 02, 2025
Increased progression free survival with radiolabelled somatostatin receptor antagonist versus standard peptide receptor radionuclide therapy in patients with somatostatin receptor positive tumours.
Journal: European journal of nuclear medicine and molecular imaging
Published: November 18, 2025
Improving the Somatostatin Receptor Status Assessment for Personalized and Precise Management of Neuroendocrine Neoplasms with the Use of a 99mTc-Radiolabeled Somatostatin Receptor Antagonist: The Final Results of the ERA PerMed TECANT Clinical Trial.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: July 14, 2025
Enhanced contrast in FAP-targeting PET imaging with 61Cu-labeled FAP inhibitors: development and preclinical evaluation of novel [61Cu]Cu-Kalios PET radioligands.
Journal: EJNMMI radiopharmacy and chemistry
Published: July 01, 2025
Targeted β--Particle Plus Conversion and Auger-Electron Therapy with 161Tb-Labeled Somatostatin Receptor Antagonist DOTA-LM3: A Phase 0 Study.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: June 17, 2025
Pyridyl-Ala in the third position of radiolabeled somatostatin antagonists: the effect of regioisomeric substitution.
Journal: EJNMMI radiopharmacy and chemistry
Published: April 08, 2025
First-in-human administration of [61Cu]Cu-NODAGA-LM3 and head-to-head comparison with [68Ga]Ga-DOTA-TOC PET/CT as part of the phase I/II COPPER PET in NET study.
Journal: European journal of nuclear medicine and molecular imaging
Published: March 12, 2025
Improving Affinity while Reducing Kidney Uptake of CXCR4-Targeting Radioligands Derived from the Endogenous Antagonist EPI-X4.
Journal: ChemMedChem
Published: September 28, 2024
Copper-61 is an advantageous alternative to gallium-68 for PET imaging of somatostatin receptor-expressing tumors: a head-to-head comparative preclinical study.
Journal: Frontiers in nuclear medicine
Published: August 15, 2024
Last Updated: 09/26/2026